Skip to content

Rates of TB treatment interruption unaffected by HIV infection or HAART

AZT resistance suppression mutations can also reduce tenofovir resistance, test tube study shows (corrected)

Double boosted protease inhibitors generate interest at Glasgow conference

High resistance levels seen in treated Ugandans: cost of therapy blamed

Truvada receives scientific approval in Europe

Once-daily abacavir receives approval in Europe

Infection with multi-drug resistant virus is lifelong, Canadian expert argues

Tenofovir/ddI: is CD4 cell loss on treatment linked to this combination?

Early virologic failure with ddI/tenofovir plus nevirapine or efavirenz